Edition:
India

People: Biomarin Pharmaceutical Inc (BMRN.OQ)

BMRN.OQ on NASDAQ Stock Exchange Global Select Market

69.15USD
18 Oct 2019
Change (% chg)

$1.25 (+1.84%)
Prev Close
$67.90
Open
$68.05
Day's High
$70.21
Day's Low
$67.75
Volume
680,518
Avg. Vol
435,678
52-wk High
$106.65
52-wk Low
$62.89

Spiegelman, Daniel 

Mr. Daniel Keith Spiegelman is Chief Financial Officer, Executive Vice President of BioMarin Pharmaceutical Inc. He joined BioMarin in May 2012 and currently serves as our Executive Vice President and Chief Financial Officer. From May 2009 until May 2012, Mr. Spiegelman served as a consultant to provide strategic financial management support to a portfolio of public and private life science companies. From 1998 to 2009, he served as Senior Vice President and Chief Financial Officer of CV Therapeutics, Inc. where he was responsible for finance, accounting, investor relations, business development, and information systems. From 1991 to 1998, Mr. Spiegelman served in various roles at Genentech, Inc., most recently as Treasurer. He received a B.A. from Stanford University and an M.B.A. from the Stanford Graduate School of Business. Mr. Spiegelman is currently a director of Cascadian Therapeutics, Inc., a public biotechnology company.

Basic Compensation

Total Annual Compensation, USD 559,231
Restricted Stock Award, USD 2,133,050
Long-Term Incentive Plans, USD --
All Other, USD 1,949,600
Fiscal Year Total, USD 4,641,880

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised 30,000 927,000.00
Name Fiscal Year Total

Jean-Jacques Bienaime

15,917,000

Daniel Spiegelman

4,641,880

Henry Fuchs

7,045,420

G. Eric Davis

2,708,210

Jeff Ajer

4,568,300

Robert Baffi

4,473,230
As Of  31 Dec 2017